抗HIV治療ガイドライン（2025年3月発行）

XV小児、青少年期における抗HIV療法

文献

  1. Guidelines for the use of antiretroviral agents in pediatric HIV infection. (米国 DHHS Dec. 19, 2024).
    https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new
  2. PENTA HIV FIRST AND SECOND LINE ANTIRETROVIRAL TREATMENT GUIDELINES 2023
    https://penta-id.org/hiv/treatment-guidelines/
  3. European AIDS Clinical Society (EACS) Guidelines. Version 12.1-November 2024.
  4. Dunn DT, Brandt CD, Kirvine A, et al. The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intrapartum transmission. AIDS. 9: F7-11. 1995.
  5. Burgard M, Blanche S, Jasseron C, et al. Performance of HIV-1 DNA or HIV-1 RNA tests for early diagnosis of perinatal HIV-1 infection during anti-retroviral prophylaxis. J Pediatr. 160(1):60-6. 2012.
  6. Guidelines for prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children. MMWR. 58[RR-11]:1-166. 2009.
  7. Centers for Disease Control and Prevention: Revised Surveillance Case Definition for HIV Infection-United States, 2014. MMWR 63(No. RR-3):1-10. 2014.
  8. Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med. 336:1337-42. 1997
  9. Mofenson LM, Korelitz J, Meyer WA, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and longterm mortality risk in HIV-1-infected children. J Infect Dis. 175:1029-38. 1997.
  10. Palumbo PE, Raskino C, Ficus S, et al. Predictive value of quantitative plasma RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA. 279:756-61. 1998.
  11. Luzuriaga K, McManus M, Mofenson L, et al. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med. 350:2471-80. 2004.
  12. Schomaker M, Leroy V, Wolfs T, et al. Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents: a multiregional analysis from Southern Africa, West Africa and Europe. Int J Epidemiol. 2017;46(2):453-465.
  13. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359(21):2233-2244. Available at: https://pubmed.ncbi.nlm.nih.gov/19020325.
  14. Shiau S, Strehlau R, Technau KG, et al. Early age at start of antiretroviral therapy associated with better virologic control after initial suppression in HIV-infected infants. AIDS. 2017;31(3):355-364. Available at: https://pubmed.ncbi.nlm.nih.gov/27828785.
  15. Massanella M, Puthanakit T, Leyre L, et al. Continuous prophylactic antiretrovirals/antiretroviral therapy since birth reduces seeding and persistence of the viral reservoir in children vertically infected with human immunodeficiency virus. Clin Infect Dis. 2021;73(3):427-438. Available at: https://pubmed.ncbi.nlm.nih.gov/32504081.
  16. Puthanakit T, Saphonn V, Ananworanich J, et al. Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. Lancet Infect Dis. 2012;12(12):933-941. Available at: https://pubmed.ncbi.nlm.nih.gov/23059199.
  17. Laughton B, Cornell M, Grove D, et al. Early antiretroviral therapy improves neurodevelopmental outcomes in infants. AIDS. 2012;26(13):1685-1690. Available at: https://pubmed.ncbi.nlm.nih.gov/22614886.
  18. Nelson BS, Tierney C, Persaud D, et al. Infants receiving very early antiretroviral therapy have high CD4 counts in the first year of life. Clin Infect Dis. 2023;76(3):e744-e747. Available at: https://pubmed.ncbi.nlm.nih.gov/36031390.
  19. Garcia-Broncano P, Maddali S, Einkauf KB, et al. Early antiretroviral therapy in neonates with HIV-1 infection restricts viral reservoir size and induces a distinct innate immune profile. Sci Transl Med. 2019;11(520). Available at: https://pubmed.ncbi.nlm.nih.gov/31776292.
  20. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 359:2233-44. 2008.
  21. Goetghebuer T, Haelterman E, Le Chenadec J, et al. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS. 2009. 23: 597-604.
  22. Cotton MF, Violari A, Otwombe K, et al. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial. Lancet. 382:1555-63. 2013.
  23. Clarke DF, Penazzato M, Capparelli E, et al. Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations. Expert Rev Clin Pharmacol.2018;11(1):83-93.
  24. Goetghebuer T, Le Chenadec J, Haelterman E, et al. Short- and long-term immunological and virological outcome in HIV-infected infants according to the age at antiretroviral treatment initiation. Clin Infect Dis. 2012;54(6):878-881. Available at: https://pubmed.ncbi.nlm.nih.gov/22198788.
  25. Shiau S, Arpadi S, Strehlau R, et al. Initiation of antiretroviral therapy before 6 months of age is associated with faster growth recovery in South African children perinatally infected with human immunodeficiency virus. J Pediatr. 2013;162(6):1138-1145 e1132. Available at: https://pubmed.ncbi.nlm.nih.gov/23312691.
  26. Iyun V, Technau KG, Eley B, et al. Earlier antiretroviral therapy initiation and decreasing mortality among HIV-infected infants initiating antiretroviral therapy within 3 months of age in South Africa, 2006–2017. Pediatr Infect Dis J. 2020;39(2):127-133. Available at: https://pubmed.ncbi.nlm.nih.gov/31725119.
  27. Tagarro A, Dominguez Rodriguez S, Violari A, et al. Poor outcome in early treated HIV perinatally infected infants in Africa. Abstract 806. Presented at: Conference on Retroviruses and Opportunistic Infections. 2020. Boston, Massachusetts. Available at: https://www.croiconference.org/abstract/poor-outcome-in-early-treated-hiv-perinatally-infected-infants-in-africa.
  28. Anderson K, Iyun V, Eley BS, et al. Hospitalization among infants who initiate antiretroviral therapy before 3  months of age. AIDS. 2023;37(3):435-445. Available at: https://pubmed.ncbi.nlm.nih.gov/36695356.
  29. Wiznia A, Stanley K, Krogstad P, et al. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial-PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team. AIDS Res Hum Retroviruses. 16:1113-21. 2004.
  30. Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13(11):927-935. Available at: https://pubmed.ncbi.nlm.nih.gov/24074642.
  31. Molina JM, Clotet B, van Lunzen J, et al. Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO. J Int AIDS Soc. 2014;17(4 Suppl 3):19490. Available at: https://pubmed.ncbi.nlm.nih.gov/25393999.
  32. Simoni JM, Montgomery A, Martin E, et al. Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics. 119:e1371-83. 2007.
  33. Puthanakit T, Aurpibul L, Lopez M, et al. Efficacy and safety of dolutegravir/lamivudine (DTG/3TC) in antiretroviral therapy (ART)-naïve adolescents living with HIV-1: DANCE study week 96 results. Presented at International AIDS Society; July 23-26, 2023, Year; Brisbane, Australia. Available at: https://medinfo.gsk.com/5f95dbd7-245e-4e65-9f36-1a99e28e5bba/450b1aad-cf09-4084-b484-0c909235ec90/450b1aad-cf09-4084-b484-0c909235ec90_viewable_rendition__v.pdf
  34. Violari A, Lindsey JC, Hughes MD, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med. 366(25):2380-9. 2012.
  35. Smith K, Kuhn L, Coovadia A, et al. Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy. AIDS. 23:1097-107. 2009.

PAGE TOP